118757-07-6

Basic information

• Product Name: 1-(1-benzenesulfonyl-2, 3-dihydro-1H-indol-5-yl)ethanone
• Synonyms: 1-(1-benzenesulfonyl-2, 3-dihydro-1H-indol-5-yl)ethanone
• CAS NO: 118757-07-6
• Molecular Weight: 301.366
• Mol File: 118757-07-6.mol

Chemical Properties

• CAS DataBase Reference: 1-(1-benzenesulfonyl-2, 3-dihydro-1H-indol-5-yl)ethanone(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(1-benzenesulfonyl-2, 3-dihydro-1H-indol-5-yl)ethanone(118757-07-6)
• EPA Substance Registry System: 1-(1-benzenesulfonyl-2, 3-dihydro-1H-indol-5-yl)ethanone(118757-07-6)

Safety Data

• Hazardous Substances Data: 118757-07-6(Hazardous Substances Data)

Upstream product

• 98-09-9 benzenesulfonyl chloride 
• 496-15-1 1-indoline 
• 81114-41-2 1-benzenesulfonyl-2,3-dihydro-1H-indole 
• 108-24-7 acetic anhydride 

Downstream Products

• 873055-25-5 5-ethyl-6-nitro-2,3-dihydro-1H-indole 
• 67932-65-4 5-ethyl-2,3-dihydro-1H-indole 
• 873055-27-7 5-ethyl-1H-indol-6-amine 
• 118757-02-1 1-benzenesulfonyl-5-ethyl-2,3-dihydro-1H-indole 
• 118757-14-5 1-(1-Benzenesulfonyl-1H-indol-5-yl)-ethanone 
• 118757-09-8 5-ethyl-1-(phenylsulfonyl)indole 

Relevant articles and documents

Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

Discovery of N -(2,4-Di- tert -butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide (VX-770, Ivacaftor), a potent and orally bioavailable CFTR potentiator

Quinolinone-3-carboxamide 1, a novel CFTR potentiator, was discovered using high-throughput screening in NIH-3T3 cells expressing the F508del-CFTR mutation. Extensive medicinal chemistry and iterative structure-activity relationship (SAR) studies to evaluate potency, selectivity, and pharmacokinetic properties resulted in the identification of N-(2,4-di-tert-butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide (VX-770, 48, ivacaftor), an investigational drug candidate approved by the FDA for the treatment of CF patients 6 years of age and older carrying the G551D mutation.

MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS

The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator, compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.

COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

Modulators of ATP-binding cassette transporters

Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.

Synthesis of Alkyl-Substituted N-Protected Indoles via Acylation and Reductive Deoxygenation

The synthesis of 2-, 3-, and 5-alkyl-1-(phenylsulfonyl)indoles involving Friedel-Crafts acylation followed by reductive deoxygenation is described.The application of this acylation-deoxygenation sequence to 3-acyl-1-(phenylsulfonyl)indoles bearing potenti